Click for best price
Gene TherapyCardiovascular Disorder Market Size, Share 2024
| Market size in 2024 |
US$ 99.00 million
|
Forecast Market size by |
US$ N/A
|
The "Global Gene Therapy in Cardiovascular Disorder Market" was valued at US$ 99.00 million in 2024 and is predicted to reach US$ 278.31 million by 2030, exhibiting a Compound Annual Growth Rate (CAGR) of 18.8% during the forecast period (2024-2030).
Gene therapy for cardiovascular disorders is a cutting-edge therapeutic approach that involves the delivery, modification, or replacement of genes within cardiovascular tissues to treat or prevent heart and vascular diseases. This innovative method aims to address the underlying genetic or molecular causes of various cardiovascular conditions, which can range from congenital heart defects and ischemic heart disease to heart failure and arrhythmias.
Key components of gene therapy in cardiovascular disorders:
-
Mechanism:
- Gene therapy utilizes vectors, often modified viruses (such as adenoviruses, lentiviruses, or adeno-associated viruses), to deliver therapeutic genes directly to heart or blood vessel cells.
- The main objectives include:
- Gene replacement: Introducing a healthy copy of a gene that is mutated or missing.
- Gene editing: Using techniques like CRISPR to modify or correct dysfunctional genes.
- Gene silencing: Reducing the expression of harmful genes that contribute to cardiovascular disease.
-
Targets and Strategies:
- Vascular diseases: Gene therapy may be employed to promote the growth of new blood vessels (angiogenesis) in conditions such as peripheral artery disease (PAD) or myocardial ischemia, where blood flow is restricted.
- Heart failure: Gene therapies can aim to enhance the contractility of heart muscles or improve their ability to regenerate.
- Genetic cardiomyopathies: Conditions such as hypertrophic cardiomyopathy (HCM) or dilated cardiomyopathy (DCM) can potentially be treated by correcting genetic mutations.
- Atherosclerosis: Gene therapies might target the reduction of cholesterol levels or the inflammation in arterial walls.
-
Advantages:
- Targeted treatment: Gene therapy can directly address the genetic basis of cardiovascular disorders, offering a more precise treatment option than conventional therapies that mainly manage symptoms.
- Long-lasting effects: A single gene therapy administration can lead to sustained therapeutic effects by permanently altering gene expression or cellular function.
- Regeneration: Gene therapy has the potential to promote tissue repair and regeneration, which is especially beneficial for damaged heart tissues.
-
Challenges:
- Delivery to target tissues: Ensuring effective delivery of therapeutic genes to the heart and vascular system poses challenges, particularly in overcoming the barriers to accessing heart tissues.
- Immune response: There is a risk of immune reactions against the vectors or the newly introduced proteins, which could diminish the efficacy of the therapy.
- Long-term effects: The long-term safety and efficacy of gene therapy in cardiovascular patients are still under investigation, requiring extensive clinical trials.
Applications in cardiovascular disorders:
- Ischemic Heart Disease: Gene therapies are being studied to enhance angiogenesis and improve blood flow in heart tissues deprived of oxygen.
- Heart Failure: Strategies are being developed to improve cardiac function by introducing genes that promote muscle contraction or protect against cell death.
- Inherited Cardiovascular Conditions: Gene therapy holds promise for correcting genetic mutations that lead to conditions like familial hypercholesterolemia or arrhythmogenic right ventricular cardiomyopathy.
Gene therapy for cardiovascular disorders represents a promising frontier in medical research, with the potential to significantly improve treatment outcomes for patients with various heart and vascular diseases. As research advances, it may lead to more effective and targeted therapies that address the root causes of these conditions.
The global key manufacturers of Gene Therapy in Cardiovascular Disorder include Renovacor, Gene Biotherapeutics, AskBio, Human Stem Cells Institute and Novartis, etc. in 2023, the global top five players have a share approximately % in terms of revenue.
Gene therapy is an experimental technique that uses genes to treat or prevent disease. In the future, this technique may allow doctors to treat a disorder by inserting a gene into a patient's cells instead of using drugs or surgery.
This report aims to provide a comprehensive presentation of the global market for Gene Therapy in Cardiovascular Disorder, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Gene Therapy in Cardiovascular Disorder. This report contains market size and forecasts of Gene Therapy in Cardiovascular Disorder in global, including the following market information:
- Global Gene Therapy in Cardiovascular Disorder Market Revenue, 2019-2024, 2025-2030, ($ millions)
- Global top five companies in 2023 (%)
We has surveyed the Gene Therapy in Cardiovascular Disorder companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Gene Therapy in Cardiovascular Disorder Market, by Type, 2019-2024, 2025-2030 ($ millions)
Global Gene Therapy in Cardiovascular Disorder Market Segment Percentages, by Type, 2023 (%)
- Viral Gene Therapy
- Non-viral Gene Therapy
Global Gene Therapy in Cardiovascular Disorder Market, by Application, 2019-2024, 2025-2030 ($ millions)
Global Gene Therapy in Cardiovascular Disorder Market Segment Percentages, by Application, 2023 (%)
- Heart Disease
- Vascular Disease
Global Gene Therapy in Cardiovascular Disorder Market, By Region and Country, 2019-2024, 2025-2030 ($ Millions)
Global Gene Therapy in Cardiovascular Disorder Market Segment Percentages, By Region and Country, 2023 (%)
- North America (United States, Canada, Mexico)
- Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe)
- Asia-Pacific (China, India, Japan, South Korea, Australia, Rest of APAC)
- The Middle East and Africa (Middle East, Africa)
- South and Central America (Brazil, Argentina, Rest of SCA)
Competitor Analysis
The report also provides analysis of leading market participants including:
- Key companies Gene Therapy in Cardiovascular Disorder revenues in global market, 2019-2024 (estimated), ($ millions)
- Key companies Gene Therapy in Cardiovascular Disorder revenues share in global market, 2023 (%)
Further, the report presents profiles of competitors in the market, key players include:
- Renovacor
- Gene Biotherapeutics
- AskBio
- Human Stem Cells Institute
- Novartis
Outline of Major Chapters:
Chapter 1: Introduces the definition of Gene Therapy in Cardiovascular Disorder, market overview.
Chapter 2: Global Gene Therapy in Cardiovascular Disorder market size in revenue.
Chapter 3: Detailed analysis of Gene Therapy in Cardiovascular Disorder company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Gene Therapy in Cardiovascular Disorder in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
| Report Attributes |
Report Details |
| Report Title |
Gene Therapy in Cardiovascular Disorder Market, Global Outlook and Forecast 2024-2030 |
| Market size in 2024 |
US$ 99.00 million
|
| Forecast Market size by |
US$ N/A
|
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2023 |
| Forecast Year |
2031 |
| Number of Pages |
65 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Gene Therapy in Cardiovascular Disorder Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Gene Therapy in Cardiovascular Disorder Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Gene Therapy in Cardiovascular Disorder Overall Market Size
2.1 Global Gene Therapy in Cardiovascular Disorder Market Size: 2023 VS 2030
2.2 Global Gene Therapy in Cardiovascular Disorder Market Size, Prospects & Forecasts: 2019-2030
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Gene Therapy in Cardiovascular Disorder Players in Global Market
3.2 Top Global Gene Therapy in Cardiovascular Disorder Companies Ranked by Revenue
3.3 Global Gene Therapy in Cardiovascular Disorder Revenue by Companies
3.4 Top 3 and Top 5 Gene Therapy in Cardiovascular Disorder Companies in Global Market, by Revenue in 2023
3.5 Global Companies Gene Therapy in Cardiovascular Disorder Product Type
3.6 Tier 1, Tier 2 and Tier 3 Gene Therapy in Cardiovascular Disorder Players in Global Market
3.6.1 List of Global Tier 1 Gene Therapy in Cardiovascular Disorder Companies
3.6.2 List of Global Tier 2 and Tier 3 Gene Therapy in Cardiovascular Disorder Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Gene Therapy in Cardiovascular Disorder Market Size Markets, 2023 & 2030
4.1.2 Viral Gene Therapy
4.1.3 Non-viral Gene Therapy
4.2 By Type - Global Gene Therapy in Cardiovascular Disorder Revenue & Forecasts
4.2.1 By Type - Global Gene Therapy in Cardiovascular Disorder Revenue, 2019-2024
4.2.2 By Type - Global Gene Therapy in Cardiovascular Disorder Revenue, 2025-2030
4.2.3 By Type - Global Gene Therapy in Cardiovascular Disorder Revenue Market Share, 2019-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Gene Therapy in Cardiovascular Disorder Market Size, 2023 & 2030
5.1.2 Heart Disease
5.1.3 Vascular Disease
5.2 By Application - Global Gene Therapy in Cardiovascular Disorder Revenue & Forecasts
5.2.1 By Application - Global Gene Therapy in Cardiovascular Disorder Revenue, 2019-2024
5.2.2 By Application - Global Gene Therapy in Cardiovascular Disorder Revenue, 2025-2030
5.2.3 By Application - Global Gene Therapy in Cardiovascular Disorder Revenue Market Share, 2019-2030
6 Sights by Region
6.1 By Region - Global Gene Therapy in Cardiovascular Disorder Market Size, 2023 & 2030
6.2 By Region - Global Gene Therapy in Cardiovascular Disorder Revenue & Forecasts
6.2.1 By Region - Global Gene Therapy in Cardiovascular Disorder Revenue, 2019-2024
6.2.2 By Region - Global Gene Therapy in Cardiovascular Disorder Revenue, 2025-2030
6.2.3 By Region - Global Gene Therapy in Cardiovascular Disorder Revenue Market Share, 2019-2030
6.3 North America
6.3.1 By Country - North America Gene Therapy in Cardiovascular Disorder Revenue, 2019-2030
6.3.2 US Gene Therapy in Cardiovascular Disorder Market Size, 2019-2030
6.3.3 Canada Gene Therapy in Cardiovascular Disorder Market Size, 2019-2030
6.3.4 Mexico Gene Therapy in Cardiovascular Disorder Market Size, 2019-2030
6.4 Europe
6.4.1 By Country - Europe Gene Therapy in Cardiovascular Disorder Revenue, 2019-2030
6.4.2 Germany Gene Therapy in Cardiovascular Disorder Market Size, 2019-2030
6.4.3 France Gene Therapy in Cardiovascular Disorder Market Size, 2019-2030
6.4.4 U.K. Gene Therapy in Cardiovascular Disorder Market Size, 2019-2030
6.4.5 Italy Gene Therapy in Cardiovascular Disorder Market Size, 2019-2030
6.4.6 Russia Gene Therapy in Cardiovascular Disorder Market Size, 2019-2030
6.4.7 Nordic Countries Gene Therapy in Cardiovascular Disorder Market Size, 2019-2030
6.4.8 Benelux Gene Therapy in Cardiovascular Disorder Market Size, 2019-2030
6.5 Asia
6.5.1 By Region - Asia Gene Therapy in Cardiovascular Disorder Revenue, 2019-2030
6.5.2 China Gene Therapy in Cardiovascular Disorder Market Size, 2019-2030
6.5.3 Japan Gene Therapy in Cardiovascular Disorder Market Size, 2019-2030
6.5.4 South Korea Gene Therapy in Cardiovascular Disorder Market Size, 2019-2030
6.5.5 Southeast Asia Gene Therapy in Cardiovascular Disorder Market Size, 2019-2030
6.5.6 India Gene Therapy in Cardiovascular Disorder Market Size, 2019-2030
6.6 South America
6.6.1 By Country - South America Gene Therapy in Cardiovascular Disorder Revenue, 2019-2030
6.6.2 Brazil Gene Therapy in Cardiovascular Disorder Market Size, 2019-2030
6.6.3 Argentina Gene Therapy in Cardiovascular Disorder Market Size, 2019-2030
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Gene Therapy in Cardiovascular Disorder Revenue, 2019-2030
6.7.2 Turkey Gene Therapy in Cardiovascular Disorder Market Size, 2019-2030
6.7.3 Israel Gene Therapy in Cardiovascular Disorder Market Size, 2019-2030
6.7.4 Saudi Arabia Gene Therapy in Cardiovascular Disorder Market Size, 2019-2030
6.7.5 UAE Gene Therapy in Cardiovascular Disorder Market Size, 2019-2030
7 Gene Therapy in Cardiovascular Disorder Companies Profiles
7.1 Renovacor
7.1.1 Renovacor Company Summary
7.1.2 Renovacor Business Overview
7.1.3 Renovacor Gene Therapy in Cardiovascular Disorder Major Product Offerings
7.1.4 Renovacor Gene Therapy in Cardiovascular Disorder Revenue in Global Market (2019-2024)
7.1.5 Renovacor Key News & Latest Developments
7.2 Gene Biotherapeutics
7.2.1 Gene Biotherapeutics Company Summary
7.2.2 Gene Biotherapeutics Business Overview
7.2.3 Gene Biotherapeutics Gene Therapy in Cardiovascular Disorder Major Product Offerings
7.2.4 Gene Biotherapeutics Gene Therapy in Cardiovascular Disorder Revenue in Global Market (2019-2024)
7.2.5 Gene Biotherapeutics Key News & Latest Developments
7.3 AskBio
7.3.1 AskBio Company Summary
7.3.2 AskBio Business Overview
7.3.3 AskBio Gene Therapy in Cardiovascular Disorder Major Product Offerings
7.3.4 AskBio Gene Therapy in Cardiovascular Disorder Revenue in Global Market (2019-2024)
7.3.5 AskBio Key News & Latest Developments
7.4 Human Stem Cells Institute
7.4.1 Human Stem Cells Institute Company Summary
7.4.2 Human Stem Cells Institute Business Overview
7.4.3 Human Stem Cells Institute Gene Therapy in Cardiovascular Disorder Major Product Offerings
7.4.4 Human Stem Cells Institute Gene Therapy in Cardiovascular Disorder Revenue in Global Market (2019-2024)
7.4.5 Human Stem Cells Institute Key News & Latest Developments
7.5 Novartis
7.5.1 Novartis Company Summary
7.5.2 Novartis Business Overview
7.5.3 Novartis Gene Therapy in Cardiovascular Disorder Major Product Offerings
7.5.4 Novartis Gene Therapy in Cardiovascular Disorder Revenue in Global Market (2019-2024)
7.5.5 Novartis Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Gene Therapy in Cardiovascular Disorder Market Opportunities & Trends in Global Market
Table 2. Gene Therapy in Cardiovascular Disorder Market Drivers in Global Market
Table 3. Gene Therapy in Cardiovascular Disorder Market Restraints in Global Market
Table 4. Key Players of Gene Therapy in Cardiovascular Disorder in Global Market
Table 5. Top Gene Therapy in Cardiovascular Disorder Players in Global Market, Ranking by Revenue (2023)
Table 6. Global Gene Therapy in Cardiovascular Disorder Revenue by Companies, (US$, Mn), 2019-2024
Table 7. Global Gene Therapy in Cardiovascular Disorder Revenue Share by Companies, 2019-2024
Table 8. Global Companies Gene Therapy in Cardiovascular Disorder Product Type
Table 9. List of Global Tier 1 Gene Therapy in Cardiovascular Disorder Companies, Revenue (US$, Mn) in 2023 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Gene Therapy in Cardiovascular Disorder Companies, Revenue (US$, Mn) in 2023 and Market Share
Table 11. By Type ? Global Gene Therapy in Cardiovascular Disorder Revenue, (US$, Mn), 2023 & 2030
Table 12. By Type - Gene Therapy in Cardiovascular Disorder Revenue in Global (US$, Mn), 2019-2024
Table 13. By Type - Gene Therapy in Cardiovascular Disorder Revenue in Global (US$, Mn), 2025-2030
Table 14. By Application ? Global Gene Therapy in Cardiovascular Disorder Revenue, (US$, Mn), 2023 & 2030
Table 15. By Application - Gene Therapy in Cardiovascular Disorder Revenue in Global (US$, Mn), 2019-2024
Table 16. By Application - Gene Therapy in Cardiovascular Disorder Revenue in Global (US$, Mn), 2025-2030
Table 17. By Region ? Global Gene Therapy in Cardiovascular Disorder Revenue, (US$, Mn), 2023 & 2030
Table 18. By Region - Global Gene Therapy in Cardiovascular Disorder Revenue (US$, Mn), 2019-2024
Table 19. By Region - Global Gene Therapy in Cardiovascular Disorder Revenue (US$, Mn), 2025-2030
Table 20. By Country - North America Gene Therapy in Cardiovascular Disorder Revenue, (US$, Mn), 2019-2024
Table 21. By Country - North America Gene Therapy in Cardiovascular Disorder Revenue, (US$, Mn), 2025-2030
Table 22. By Country - Europe Gene Therapy in Cardiovascular Disorder Revenue, (US$, Mn), 2019-2024
Table 23. By Country - Europe Gene Therapy in Cardiovascular Disorder Revenue, (US$, Mn), 2025-2030
Table 24. By Region - Asia Gene Therapy in Cardiovascular Disorder Revenue, (US$, Mn), 2019-2024
Table 25. By Region - Asia Gene Therapy in Cardiovascular Disorder Revenue, (US$, Mn), 2025-2030
Table 26. By Country - South America Gene Therapy in Cardiovascular Disorder Revenue, (US$, Mn), 2019-2024
Table 27. By Country - South America Gene Therapy in Cardiovascular Disorder Revenue, (US$, Mn), 2025-2030
Table 28. By Country - Middle East & Africa Gene Therapy in Cardiovascular Disorder Revenue, (US$, Mn), 2019-2024
Table 29. By Country - Middle East & Africa Gene Therapy in Cardiovascular Disorder Revenue, (US$, Mn), 2025-2030
Table 30. Renovacor Company Summary
Table 31. Renovacor Gene Therapy in Cardiovascular Disorder Product Offerings
Table 32. Renovacor Gene Therapy in Cardiovascular Disorder Revenue (US$, Mn) & (2019-2024)
Table 33. Renovacor Key News & Latest Developments
Table 34. Gene Biotherapeutics Company Summary
Table 35. Gene Biotherapeutics Gene Therapy in Cardiovascular Disorder Product Offerings
Table 36. Gene Biotherapeutics Gene Therapy in Cardiovascular Disorder Revenue (US$, Mn) & (2019-2024)
Table 37. Gene Biotherapeutics Key News & Latest Developments
Table 38. AskBio Company Summary
Table 39. AskBio Gene Therapy in Cardiovascular Disorder Product Offerings
Table 40. AskBio Gene Therapy in Cardiovascular Disorder Revenue (US$, Mn) & (2019-2024)
Table 41. AskBio Key News & Latest Developments
Table 42. Human Stem Cells Institute Company Summary
Table 43. Human Stem Cells Institute Gene Therapy in Cardiovascular Disorder Product Offerings
Table 44. Human Stem Cells Institute Gene Therapy in Cardiovascular Disorder Revenue (US$, Mn) & (2019-2024)
Table 45. Human Stem Cells Institute Key News & Latest Developments
Table 46. Novartis Company Summary
Table 47. Novartis Gene Therapy in Cardiovascular Disorder Product Offerings
Table 48. Novartis Gene Therapy in Cardiovascular Disorder Revenue (US$, Mn) & (2019-2024)
Table 49. Novartis Key News & Latest Developments
List of Figures
Figure 1. Gene Therapy in Cardiovascular Disorder Segment by Type in 2023
Figure 2. Gene Therapy in Cardiovascular Disorder Segment by Application in 2023
Figure 3. Global Gene Therapy in Cardiovascular Disorder Market Overview: 2023
Figure 4. Key Caveats
Figure 5. Global Gene Therapy in Cardiovascular Disorder Market Size: 2023 VS 2030 (US$, Mn)
Figure 6. Global Gene Therapy in Cardiovascular Disorder Revenue, 2019-2030 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Gene Therapy in Cardiovascular Disorder Revenue in 2023
Figure 8. By Type - Global Gene Therapy in Cardiovascular Disorder Revenue Market Share, 2019-2030
Figure 9. By Application - Global Gene Therapy in Cardiovascular Disorder Revenue Market Share, 2019-2030
Figure 10. By Type - Global Gene Therapy in Cardiovascular Disorder Revenue, (US$, Mn), 2023 & 2030
Figure 11. By Type - Global Gene Therapy in Cardiovascular Disorder Revenue Market Share, 2019-2030
Figure 12. By Application - Global Gene Therapy in Cardiovascular Disorder Revenue, (US$, Mn), 2023 & 2030
Figure 13. By Application - Global Gene Therapy in Cardiovascular Disorder Revenue Market Share, 2019-2030
Figure 14. By Region - Global Gene Therapy in Cardiovascular Disorder Revenue Market Share, 2019-2030
Figure 15. By Country - North America Gene Therapy in Cardiovascular Disorder Revenue Market Share, 2019-2030
Figure 16. US Gene Therapy in Cardiovascular Disorder Revenue, (US$, Mn), 2019-2030
Figure 17. Canada Gene Therapy in Cardiovascular Disorder Revenue, (US$, Mn), 2019-2030
Figure 18. Mexico Gene Therapy in Cardiovascular Disorder Revenue, (US$, Mn), 2019-2030
Figure 19. By Country - Europe Gene Therapy in Cardiovascular Disorder Revenue Market Share, 2019-2030
Figure 20. Germany Gene Therapy in Cardiovascular Disorder Revenue, (US$, Mn), 2019-2030
Figure 21. France Gene Therapy in Cardiovascular Disorder Revenue, (US$, Mn), 2019-2030
Figure 22. U.K. Gene Therapy in Cardiovascular Disorder Revenue, (US$, Mn), 2019-2030
Figure 23. Italy Gene Therapy in Cardiovascular Disorder Revenue, (US$, Mn), 2019-2030
Figure 24. Russia Gene Therapy in Cardiovascular Disorder Revenue, (US$, Mn), 2019-2030
Figure 25. Nordic Countries Gene Therapy in Cardiovascular Disorder Revenue, (US$, Mn), 2019-2030
Figure 26. Benelux Gene Therapy in Cardiovascular Disorder Revenue, (US$, Mn), 2019-2030
Figure 27. By Region - Asia Gene Therapy in Cardiovascular Disorder Revenue Market Share, 2019-2030
Figure 28. China Gene Therapy in Cardiovascular Disorder Revenue, (US$, Mn), 2019-2030
Figure 29. Japan Gene Therapy in Cardiovascular Disorder Revenue, (US$, Mn), 2019-2030
Figure 30. South Korea Gene Therapy in Cardiovascular Disorder Revenue, (US$, Mn), 2019-2030
Figure 31. Southeast Asia Gene Therapy in Cardiovascular Disorder Revenue, (US$, Mn), 2019-2030
Figure 32. India Gene Therapy in Cardiovascular Disorder Revenue, (US$, Mn), 2019-2030
Figure 33. By Country - South America Gene Therapy in Cardiovascular Disorder Revenue Market Share, 2019-2030
Figure 34. Brazil Gene Therapy in Cardiovascular Disorder Revenue, (US$, Mn), 2019-2030
Figure 35. Argentina Gene Therapy in Cardiovascular Disorder Revenue, (US$, Mn), 2019-2030
Figure 36. By Country - Middle East & Africa Gene Therapy in Cardiovascular Disorder Revenue Market Share, 2019-2030
Figure 37. Turkey Gene Therapy in Cardiovascular Disorder Revenue, (US$, Mn), 2019-2030
Figure 38. Israel Gene Therapy in Cardiovascular Disorder Revenue, (US$, Mn), 2019-2030
Figure 39. Saudi Arabia Gene Therapy in Cardiovascular Disorder Revenue, (US$, Mn), 2019-2030
Figure 40. UAE Gene Therapy in Cardiovascular Disorder Revenue, (US$, Mn), 2019-2030
Figure 41. Renovacor Gene Therapy in Cardiovascular Disorder Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 42. Gene Biotherapeutics Gene Therapy in Cardiovascular Disorder Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 43. AskBio Gene Therapy in Cardiovascular Disorder Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 44. Human Stem Cells Institute Gene Therapy in Cardiovascular Disorder Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 45. Novartis Gene Therapy in Cardiovascular Disorder Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
